Collaborations & Alliances

Oxford Bio Receives Boehringer Milestone

Advances immuno-oncology programs leveraging the OGAP target discovery platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oxford BioTherapeutics Ltd. has received a milestone payment from Boehringer Ingelheim (BI) under the companies’ alliance for the discovery of novel cancer antibody therapeutic targets using OBT’s OGAP target discovery platform. In addition to OBT’s two clinical stage assets, MEN1309/OBT076 and MEN1112/OBT357, the BI drug candidate is one of several immuno-oncology programs leveraging the OGAP target discovery platform. “OBT’s platforms are designed to discover novel therapeutic targets and e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters